Recombinant Human VEGFR2/KDR Protein, hFc-His-重组蛋白-北京百欧泰生物科技有限公司

Content

抗体产品
- 一抗
  - --|--|流式抗体
  - --|--|单克隆抗体
  - --|--|重组兔单抗
  - --|--|多克隆抗体
  - --|--|小分子抗原抗体
  - --|--|抗体对
  - --|--|标签抗体
  - --|--|修饰性抗体
  - --|--|其他抗体
- 二抗
- 试剂盒
  - --|--|标记试剂盒
  - --|--|其他试剂盒
  - --|--|标记染料
蛋白产品
生物材料
- 金属纳米材料
  - --|--|金纳米颗粒
  - --|--|金纳米棒
  - --|--|银纳米颗粒
  - --|--|金纳米海胆
  - --|--|碳纳米颗粒
  - --|--|特殊形状纳米颗粒
- 磁性微球
  - --|--|PS Magnetic Particles
  - --|--|Silica Magnetic Particles
  - --|--|Fe3O4 Magnetic Particles
  - --|--|Functionalized Magnetic Particles
  - --|--|Magnetic Particles Conjugates
  - --|--|Fe2O3 Magnetic Particles
  - --|--|UF Magnetic Particles
  - --|--|Conjugation Kit
  - --|--|Other Magnetic Particles
  - --|--|磁力架
- 单分散微球
  - --|--|聚苯乙烯微球
  - --|--|二氧化硅微球
  - --|--|PMMA 微球
  - --|--|PET 微球
  - --|--|PVA 微球
  - --|--|PVC 微球
  - --|--|DVB 微球
  - --|--|PP 微球
  - --|--|PE 微球
  - --|--|GMA 微球
  - --|--|PLA微球
  - --|--|PLGA微球
  - --|--|PLLA微球
  - --|--|PDLA微球
- 其他材料
  - --|--|上转换纳米颗粒
  - --|--|量子点
  - --|--|荧光微球
  - --|--|色谱填料
热销产品
- 猴痘相关产品
- 新冠相关产品
- 外泌体相关产品
- 常用试剂
  - --|--|转染试剂
  - --|--|ELISA-FCM试剂
  - --|--|WB试剂
  - --|--|IHC-ICC-IF试剂
  - --|--|载体材料

Contact us

Biotyscience Inc

Tel 400-669-8850

E-mail info@biotyscience.com

QQ 499854788

82458988

Recombinant Human VEGFR2/KDR Protein, hFc-His

Description
Documentation
Citations

Cat No	BIOP3131
Conjugate
Type	生长因子
Source	HEK293
Tag	hFc-His
Size	20 ug
Application	Immunogen
Format	Lyophilized
Concentration	Please refer to the vial lable for the specific concentration.
Buffer	Supplied in PBS, pH 7.4.
Species	Human
Storage	Store at –20 degree. Avoid repeated freeze/thaw cycles.
Synonyms	KDR;CD309;FLK1;VEGFR;VEGFR2
Purification	> 95% by SDS-PAGE.
MolecularWeight
Description
Background	Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling are critical to endothelial cell survival, maintenance of the vasculature and alveolar structure, and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.

We can offer labeled proteins/antibodies using a broad range of intensely fluorescent dyes and labels including FITC, Biotin, Alexa Fluor, Rhodamine B, Cy, Co-Au.

上一篇：Recombinant human FGF-19 Protein(aa 27-216), His 下一篇：Recombinant Human Angiopoietin-2/ANGPT2 Protein, His-Avi

重组蛋白

Content

Download

Contact us

Recombinant Human VEGFR2/KDR Protein, hFc-His